Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2015-12-06 Regulatory Filings
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Regeneus to present at Austrade Mission on Regenmed in Japan 2 pages 191.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about Regeneus Ltd's CEO presenting at an Austrade mission on regenerative medicine opportunities in Japan. It discusses the event details, market opportunities, and company plans but does not contain financial statements, earnings data, or detailed financial analysis. The document is relatively short (4066 characters) and serves as a corporate announcement about a presentation and business development activity rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention any report being published or attached. The content aligns best with a general regulatory announcement about company activities and presentations, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2015-12-06 English
Presentation for Austrade Mission on Regenmed in Japan 26 pages 4.8MB
Investor Presentation Classification · 95% confidence The document is titled 'Corporate Presentation for Austrade Mission on Regenerative Medicine Opportunities in Japan' and contains detailed information about the company's product pipeline, clinical trials, technology platforms, market opportunities, and strategic updates. It includes forward-looking statements, executive summaries, product development updates, and market analysis. The content is structured as a presentation with agenda items, slides, and detailed descriptions of products and trials. There is no indication that this is a formal financial report, audit, regulatory filing, or legal document. It is clearly a presentation aimed at investors or stakeholders to inform them about the company's strategy, products, and market position. Therefore, the document fits the definition of an Investor Presentation (IP).
2015-12-06 English
Canine cancer vaccine trial on lymphoma at SASH commenced 2 pages 207.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of a clinical trial for a canine cancer vaccine by Regeneus. It provides details about the trial, the technology, and background information on the disease and company. There are no financial statements, regulatory filings, voting results, or management changes. The content is informational and promotional about a new trial, typical of a press release. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature and content, the best fitting category is a general Regulatory Filing (RNS) as a press release announcement that does not fit other specific categories.
2015-11-25 English
High potency stem cells for next generation cell therapies 2 pages 202.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 24 November 2015 from Regeneus Ltd about securing exclusive rights to commercialize a breakthrough stem cell technology. It discusses the technology, collaboration, commercial opportunities, and company background. There are no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no mention of report attachments or filings. The content is a corporate announcement about a technology licensing and collaboration agreement, which fits best under Capital/Financing Update (CAP) as it relates to commercial rights and potential revenue streams from a new technology. The document length is moderate and contains substantive information about the business development rather than just a brief notice or report publication announcement.
2015-11-23 English
Patent granted for allogeneic stem cell technology platform 2 pages 193.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 11 November 2015, reporting the granting of a key patent for the company's allogeneic stem cell technology platform. It discusses the patent details, the technology, and ongoing clinical trials. The document is relatively short (3578 characters) and focuses on a specific corporate update regarding intellectual property rights. There is no financial data, no detailed financial report, no management discussion of financial results, no voting results, no regulatory certification, or other report types. It is a corporate announcement about a patent grant, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or others. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and corporate updates that do not fit other categories.
2015-11-10 English
Chairman's Address To Shareholders 2 pages 205.2KB
AGM Information Classification · 95% confidence The document is titled '2015 Annual General Meeting Chairman’s Address' and is an ASX announcement. It contains a speech given at the Annual General Meeting (AGM) discussing the company's progress, strategic focus, clinical trials, patents, and outlook. There is no detailed financial data or comprehensive financial statements, but rather a presentation of information typically shared during an AGM. The length is 7729 characters, which is consistent with a detailed AGM presentation or address. The content is focused on company updates and strategic direction rather than a formal annual report or financial filing. Therefore, this document fits the category of AGM Information (AGM-R).
2015-11-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.